Skip to main content
OpenTrials
Completed

NCT Number: NCT04715737

Differential Effects of Vasopressin and Oxytocin on Attention Control

The main aim of the present study is to investigate whether intranasal vasopressin (20IU) and oxytocin (24IU) have differential effects on attention control in a social-emotional saccade/antisaccade eye-tracking paradigm.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–30 year

Sex eligibility

Male

Study type

Interventional

Phase

Not applicable

Primary location

University of Electronic Science and Technology of China (UESTC)

Sichuan, Chengdu, 611731, China

About this study

Previous studies have demonstrated intranasal vasopressin and oxytocin's divergent effects on social behavior and emotion processing such as empathy and negative emotion processing, however, it remains unclear whether vasopressin and oxytocin treatment would have differential effects on attention processing to social stimuli. Based on the previous registered studies (ClinicalTrials.gov ID: NCT04493554 and NCT03486925) from our group using a validated emotional anti-saccade task with social stimuli (emotional faces) and non-social stimuli (oval shape) have separately explored intranasal vasopressin and oxytocin's modulatory effects on attention processing, the present study aims to conduct a secondary analysis of the previously acquired data to directly compare vasopressin and oxytocin's effects on attention control to social emotional stimuli. To this end data from subjects who underwent intranasal oxytocin administration (n = 33; NCT03486925) will be compared with data from subjects who underwent intranasal vasopressin or placebo administration (n = 39, or 45 respectively; NCT04493554). To further control for non-treatment related factors the intranasal placebo groups from the previous studies (ClinicalTrials.gov ID: NCT04493554 and NCT03486925) will be compared with respect to primary and secondary outcome measures of the trial, in particular general and emotion-specific effects on attentional control.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male, healthy participants
  • Non smokers

Exclusion criteria

  • Previous or current medical, psychiatric, neurological disorder
  • Regular medication
  • Use of any psychoactive substances in the 24 hours before experiment

Treatment and study plan

Vasopressin

Drug

Administration of vasopressin (20IU) intranasally

Oxytocin

Drug

Administration of oxytocin (24IU) intranasally

Placebo

Drug

Administration of placebo intranasally

Primary outcomes

  1. Differential effects of intranasal vasopressin and oxytocin administration on saccade/antisaccade latencies towards social (facial) versus non-social (shape) stimuli

    Time frame: Time Frame: 45 minutes - 100 minutes after treatment

    Comparison between social-specific saccade/antisaccade latencies (in milliseconds) between the vasopressin, oxytocin and placebo treatment conditions

  2. Differential effects of intranasal vasopressin and oxytocin administration on error rates of saccade/antisaccade for social (facial) versus non-social (shape) stimuli

    Time frame: Time Frame: 45 minutes - 100 minutes after treatment

    Comparison between social-specific error rates of saccade/antisaccade between the vasopressin, oxytocin and placebo treatment conditions

Secondary outcomes

  1. Emotion-specific effects of vasopressin and oxytocin administration on saccade/antisaccade latencies towards the separate facial emotions

    Time frame: Time Frame: 45 minutes - 100 minutes after treatment

    Comparison between emotion-specific saccade/antisaccade latencies (in milliseconds) between the vasopressin, oxytocin and placebo treatment conditions

  2. Emotion-specific effects of vasopressin and oxytocin administration on saccade/antisaccade error rates for the separate facial emotions

    Time frame: Time Frame: 45 minutes - 100 minutes after treatment

    Comparison between emotion-specific saccade/antisaccade error rates between the vasopressin, oxytocin and placebo treatment conditions

Sponsors and collaborators

Lead sponsor

University of Electronic Science and Technology of China

Other

Registry information

Official study title

The Differential Effects of Intranasal Vasopressin and Oxytocin on Attention Control

Important dates

Study start
2017
Primary completion
2021
Study completion
2021
First posted
Jan 20, 2021
Registry last updated
Jan 22, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.